Atovaquone
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Glaxo Wellcome, GlaxoSmithKline, University of Oxford, Baylor College of Medicine
Conditions
Acute Myeloid LeukemiaBacterial InfectionsCarcinoma, Non-Small-Cell LungDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantHIV InfectionsHigh-grade GliomaMalaria
Early Phase 1
Phase 1
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children
CompletedNCT00000773
End: 1996-09-30Target: 24Updated: 2021-10-28
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
CompletedNCT01858831
Start: 2012-04-30End: 2012-05-31Updated: 2017-03-22
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
RecruitingNCT06624371
Start: 2025-03-28End: 2027-10-31Target: 18Updated: 2025-07-22
Phase 2
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
CompletedNCT00001996
Updated: 2005-06-24
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
CompletedNCT00000794
End: 1998-04-30Target: 100Updated: 2021-10-28
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
CompletedNCT00000655
Target: 300Updated: 2011-03-01
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
CompletedNCT00000811
End: 2001-11-30Target: 690Updated: 2021-11-04
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
RecruitingNCT05998135
Start: 2023-11-09End: 2027-06-30Target: 28Updated: 2025-09-11
Phase 3
A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX
CompletedNCT00002340
Target: 615Updated: 2005-06-24
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
CompletedNCT00000802
End: 1997-07-31Target: 700Updated: 2021-11-04
Phase 4
Unknown Phase
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine
CompletedNCT00001990
Updated: 2005-06-24
A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
CompletedNCT00001991
Updated: 2005-06-24
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
CompletedNCT00001994
Updated: 2005-06-24